nContact starts trial of ablation guidance device
This article was originally published in Clinica
A study investigating Numeris, an ablation guidance system developed by nContact Surgical (Morrisville, North Carolina), in the treatment of symptomatic paroxysmal atrial fibrillation has been initiated. The US-based feasibility clinical trial will evaluate the safety and efficacy of the coagulation guidance system along with a commercially available ablation catheter, Biosense Webster's NaviStar ThermoCool catheter. John Funkhouser, president and CEO of nContact, said that the procedure involves a closed chest endoscopic approach, without lung deflation, and while the heart is beating.